OA01.03 Immune Checkpoint Inhibitor Dose Adaptation During the COVID-19 Pandemic in Non-Small Cell Lung Cancer– a Single-Center Experience

por Hijmering-Kappelle, L., Hiltermann, T.j.n., Bensch, F.
Publicado 2021

Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer During the COVID-19 Pandemic

por Hijmering-Kappelle, L.B.M., Hiltermann, T.J.N, Bensch, F.
Publicado 2022

Health-related problems in adult cancer survivors: development and validation of the Cancer Survivor Core Set

por Geerse, O.P., Wynia, K., Kruijer, M., Schotsman, M.J., Hiltermann, T.J.N., Berendsen, A.J.
Publicado 2016

Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis

por Suazo-Zepeda, E., Bokern, M., Vinke, P. C., Hiltermann, T. J. N., de Bock, G. H., Sidorenkov, G.
Publicado 2021

Treatment goals and changes over time in older patients with non-curable cancer

por Stegmann, M. E., Brandenbarg, D., Reyners, A. K. L., van Geffen, W. H., Hiltermann, T. J. N., Berendsen, A. J.
Publicado 2020

OTHR-01. Unmet clinical needs in patients with brain metastases in the current treatment era

por Eggen, Annemarie C, Bosma, Ingeborg, Hiltermann, Thijo J N, Hospers, Geke A P, Reyners, Anna K L, Jalving, Mathilde
Publicado 2021

Correspondence between primary and secondary care about patients with cancer: A qualitative mixed‐methods analysis

por Stegmann, Mariken E., Meijer, Jiska M., Nuver, Janine, Havenga, Klaas, Hiltermann, Thijo J.N., Maduro, John H., Schuling, Jan, Berendsen, Annette J.
Publicado 2018

Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer

por Donker, H. C., van Es, B., Tamminga, M., Lunter, G. A., van Kempen, L. C. L. T., Schuuring, E., Hiltermann, T. J. N., Groen, H. J. M.
Publicado 2023

Correspondence between primary and secondary care about patients with cancer: a Delphi consensus study

por Stegmann, M. E., Homburg, T. M., Meijer, J. M., Nuver, J., Havenga, K., Hiltermann, T. J. N., Maduro, J. H., Schuling, J., Brandenbarg, D., Berendsen, A. J.
Publicado 2019

An exploratory study of volumetric analysis for assessing tumor response with (18)F-FAZA PET/CT in patients with advanced non-small-cell lung cancer (NSCLC)

por Kerner, Gerald S. M. A., Bollineni, Vikram R., Hiltermann, Thijo J. N., Sijtsema, Nanna M., Fischer, Alexander, Bongaerts, Alphons H. H., Pruim, Jan, Groen, Harry J. M.
Publicado 2016

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression

por van der Wekken, A. J., Kuiper, J. L., Saber, A., Terpstra, M. M., Wei, J., Hiltermann, T. J. N., Thunnissen, E., Heideman, D. A. M., Timens, W., Schuuring, E., Kok, K., Smit, E. F., van den Berg, A., Groen, H. J. M.
Publicado 2017

Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome

por Kerner, Gerald S. M. A., Schuuring, Ed, Sietsma, Johanna, Hiltermann, Thijo J. N., Pieterman, Remge M., de Leede, Gerard P. J., van Putten, John W. G., Liesker, Jeroen, Renkema, Tineke E. J., van Hengel, Peter, Platteel, Inge, Timens, Wim, Groen, Harry J. M.
Publicado 2013

LBA8 Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors

por Oosting, S., Van der Veldt, A.A.M., GeurtsvanKessel, C.H., Fehrmann, R.S.N., van Binnendijk, R.S., Dingemans, A-M.C., Smit, E.F.F., Hiltermann, T.J.N., den Hartog, G., Jalving, M., Westphal, T., Battacharya, A., van der Heiden, M., Blank, C.U., Koopmans, M.P., van Els, C.A., Rots, N.Y., van Baarle, D., Haanen, J.B.A.G., de Vries, E.G.
Publicado 2021

Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors

por Oosting, S.F., van der Veldt, A.A.M., Fehrmann, R.S.N., Bhattacharya, A., van Binnendijk, R.S., GeurtsvanKessel, C.H., Dingemans, A.-M.C., Smit, E.F., Hiltermann, T.J.N., den Hartog, G., Jalving, M., Westphal, T.T., de Wilt, F., Ernst, S.M., Boerma, A., van Zijl, L., Rimmelzwaan, G.F., Kvistborg, P., van Els, C.A.C.M., Rots, N.Y., van Baarle, D., Haanen, J.B.A.G., de Vries, E.G.E.
Publicado 2023

One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment

por van der Veldt, A.A.M., Oosting, S.F., Fehrmann, R.S.N., GeurtsvanKessel, C.H., van Binnendijk, R.S., Dingemans, A.-M.C., Smit, E.F., Hiltermann, T.J.N., Hartog, G. den, Jalving, M., Westphal, T.T., Bhattacharya, A., de Wilt, F., Ernst, S.M., Boerma, A., van Zijl, L., Rimmelzwaan, G.F., Kvistborg, P., van Els, C.A.C.M., Rots, N.Y., van Baarle, D., Haanen, J.B.A.G., de Vries, E.G.E.
Publicado 2023